ATE178214T1 - System zur verbesserten in-vivo aussonderung diagnostischer und/oder therapeutischer wirkstoffe durch extrakorporales entfernen der wirkstoffe - Google Patents
System zur verbesserten in-vivo aussonderung diagnostischer und/oder therapeutischer wirkstoffe durch extrakorporales entfernen der wirkstoffeInfo
- Publication number
- ATE178214T1 ATE178214T1 AT92903020T AT92903020T ATE178214T1 AT E178214 T1 ATE178214 T1 AT E178214T1 AT 92903020 T AT92903020 T AT 92903020T AT 92903020 T AT92903020 T AT 92903020T AT E178214 T1 ATE178214 T1 AT E178214T1
- Authority
- AT
- Austria
- Prior art keywords
- active substances
- diagnostic
- improved
- extracorporeal removal
- target
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 239000013543 active substance Substances 0.000 title 2
- 238000001727 in vivo Methods 0.000 title 1
- 238000000926 separation method Methods 0.000 title 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 239000012141 concentrate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Nanotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- External Artificial Organs (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9100142A SE9100142L (sv) | 1991-01-17 | 1991-01-17 | En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE178214T1 true ATE178214T1 (de) | 1999-04-15 |
Family
ID=20381639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92903020T ATE178214T1 (de) | 1991-01-17 | 1992-01-15 | System zur verbesserten in-vivo aussonderung diagnostischer und/oder therapeutischer wirkstoffe durch extrakorporales entfernen der wirkstoffe |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6251394B1 (de) |
| EP (1) | EP0567514B1 (de) |
| JP (1) | JP3471352B2 (de) |
| AT (1) | ATE178214T1 (de) |
| CA (1) | CA2100256C (de) |
| DE (1) | DE69228802T2 (de) |
| DK (1) | DK0567514T3 (de) |
| ES (1) | ES2130167T3 (de) |
| SE (1) | SE9100142L (de) |
| WO (1) | WO1992012730A1 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6075010A (en) * | 1992-06-09 | 2000-06-13 | Neorx Corporation | Small molecular weight ligand-hexose containing clearing agents |
| US6416738B1 (en) | 1973-12-07 | 2002-07-09 | Neorx Corporation | Pretargeting methods and compounds |
| DK0436717T3 (da) * | 1989-08-02 | 2003-05-05 | Mitra Medical Technology Ab | System til anvendelse ved en fremgangsmåde til terapeutisk eller diagnostisk behandling |
| US6217869B1 (en) | 1992-06-09 | 2001-04-17 | Neorx Corporation | Pretargeting methods and compounds |
| US6358490B2 (en) | 1992-06-09 | 2002-03-19 | Neorx Corporation | Three-step pretargeting methods and compounds |
| US5911969A (en) | 1992-06-09 | 1999-06-15 | Neorx Corporation | Pretargeting protocols for enhanced localization of active agents to target sites |
| US6015897A (en) * | 1993-12-07 | 2000-01-18 | Neorx Corporation | Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota |
| CA2178477A1 (en) * | 1993-12-07 | 1995-06-15 | Louis J. Theodore | Pretargeting methods and compounds |
| AU2191795A (en) * | 1994-03-23 | 1995-10-09 | Alexion Pharmaceuticals, Inc. | Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation |
| US6172045B1 (en) | 1994-12-07 | 2001-01-09 | Neorx Corporation | Cluster clearing agents |
| US6908903B1 (en) | 1994-12-07 | 2005-06-21 | Aletheon Pharmaceuticals, Inc. | Cluster clearing agents |
| RU2219949C2 (ru) * | 1996-01-11 | 2003-12-27 | Перигрин Фармасьютикалс Инк. | Антитела с уменьшенным суммарным положительным зарядом |
| US20010023288A1 (en) | 1999-07-07 | 2001-09-20 | Wilbur D. Scott | Trifunctional reagent for conjugation to a biomolecule |
| PT1049499E (pt) * | 1998-01-20 | 2004-03-31 | Mitra Medical Technology Ab | Aparelho para uso na extraccao de elementos especialmente anticorpos exogenos presentes no sangue ou no plasma |
| US6533734B1 (en) * | 1999-06-11 | 2003-03-18 | The Board Of Trustees Of The University Of Illinois | Time-integrated sampler of bodily fluid |
| IT1310933B1 (it) * | 1999-11-16 | 2002-02-27 | Luigi Benatti | Macchina multifunzionale per il monitoraggio ed il controllo diterapie locoregionali in oncologia. |
| SE0002287D0 (sv) | 2000-06-16 | 2000-06-16 | Department Of Radiation Oncolo | Biotinderivat |
| PL359328A1 (en) * | 2000-06-16 | 2004-08-23 | Mitra Medical Technology Ab | Reusable extracorporeal colums loaded with ligand-dibiotin conjugates |
| EP1420641A4 (de) * | 2001-08-01 | 2005-05-25 | Anil K Chauhan | Immunkomplexe |
| WO2003090781A1 (en) * | 2002-04-23 | 2003-11-06 | Meir Strahilevitz | Methods and devices for targeting a site in a mammal and for removing species from a mammal |
| US20040044300A1 (en) * | 2002-09-03 | 2004-03-04 | Donnie Rudd | Method of replenishing cells damaged by treatment for cancer |
| US20040077985A1 (en) * | 2002-09-03 | 2004-04-22 | Donnie Rudd | Method of replenishing cells damaged by treatment for cancer |
| US20040208865A1 (en) * | 2003-02-12 | 2004-10-21 | Chauhan Anil K. | Immune complexes |
| US20080075704A1 (en) * | 2005-02-28 | 2008-03-27 | Wolf David A | Method of providing readily available cellular material derived from peripheral blood, and a composition thereof |
| US20060193839A1 (en) * | 2005-02-28 | 2006-08-31 | Donnie Rudd | Method of providing readily available cellular material derived from peripheral blood, and a composition thereof |
| US20110014151A1 (en) * | 2006-01-11 | 2011-01-20 | Biotech Igg Ab | Macromolecule conjugate |
| WO2012142180A1 (en) * | 2011-04-12 | 2012-10-18 | Tianxin Wang | Methods to detect and treat diseases |
| US9549953B2 (en) * | 2011-12-08 | 2017-01-24 | Eliaz Therapeutics, Inc. | Galectin-3 plasmapheresis therapy |
| JP6170077B2 (ja) | 2012-02-16 | 2017-07-26 | エータイアー ファーマ， インコーポレイテッド | 自己免疫および炎症疾患を処置するためのヒスチジルｔＲＮＡ合成酵素 |
| JP6397479B2 (ja) | 2013-03-15 | 2018-09-26 | エータイアー ファーマ， インコーポレイテッド | ヒスチジル−ｔＲＮＡシンテターゼＦｃコンジュゲート |
| AU2018256435B2 (en) | 2017-04-20 | 2025-03-13 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4375414A (en) | 1971-05-20 | 1983-03-01 | Meir Strahilevitz | Immunological methods for removing species from the blood circulatory system and devices therefor |
| US4371515A (en) | 1978-12-26 | 1983-02-01 | E-Y Laboratories, Inc. | Method for forming an isolated lectin-immunological conjugate |
| US4223672A (en) | 1979-02-08 | 1980-09-23 | Baxter Travenol Laboratories, Inc. | Variable volume plasma treatment chamber for an apparatus for the extracorporeal treatment of disease |
| US4215688A (en) | 1979-02-09 | 1980-08-05 | Baxter Travenol Laboratories, Inc. | Apparatus for the extracorporeal treatment of disease |
| US4350156A (en) | 1980-05-29 | 1982-09-21 | Japan Foundation For Artificial Organs | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid |
| US4824432A (en) | 1981-03-24 | 1989-04-25 | S.V.S. Laboratories, Inc. | Method for treating AIDS and other immune deficiencies and immune disorders |
| US4687808A (en) | 1982-08-12 | 1987-08-18 | Biospecific Technologies, Inc. | Activation of biocompatible polymers with biologicals whose binding complements are pathological effectors |
| CA1221307A (en) * | 1982-12-02 | 1987-05-05 | Nobutaka Tani | Adsorbent and process for preparing the same |
| CA1236738A (en) | 1983-06-01 | 1988-05-17 | Mark R. Honard | Therapeutic device |
| US4551435A (en) | 1983-08-24 | 1985-11-05 | Immunicon, Inc. | Selective removal of immunospecifically recognizable substances from solution |
| US4863713A (en) | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
| US4877599A (en) | 1986-11-10 | 1989-10-31 | New England Deaconess Hospital Corporation | Detection of vascular disease with labelled antibodies |
| US5122112A (en) * | 1986-11-21 | 1992-06-16 | Imre Corporation | Antigen-specific removal of circulating immune complexes |
| US4800016A (en) | 1986-11-24 | 1989-01-24 | The University Of Michigan | Extracorporeal blood de-heparinization system |
| DE3705637A1 (de) * | 1987-02-21 | 1988-09-29 | Bissendorf Peptide Gmbh | Vorrichtung zur entfernung von lokal applizierten wirkstoffen gegen solide tumoren |
| US4846786A (en) | 1987-04-30 | 1989-07-11 | Massachusetts Institute Of Technology | Bioreactor containing suspended, immobilized species |
| US4885207A (en) * | 1987-07-13 | 1989-12-05 | Uop | Biocompatible protein or ligand immobilization system |
| US4865841A (en) | 1987-10-23 | 1989-09-12 | Imre Corporation | Methods and compositions for transient elimination of humoral immune antibodies |
| US5069662A (en) * | 1988-10-21 | 1991-12-03 | Delcath Systems, Inc. | Cancer treatment |
| US5149425A (en) | 1988-11-09 | 1992-09-22 | Chembiomed, Ltd. | Affinity supports for hemoperfusion |
| DK0454783T3 (da) * | 1989-01-23 | 1995-10-16 | Akzo Nobel Nv | Sted-specifik in vivo aktivering af terapeutiske lægemidler |
| US5252466A (en) * | 1989-05-19 | 1993-10-12 | Biotechnology Research And Development Corporation | Fusion proteins having a site for in vivo post-translation modification and methods of making and purifying them |
| DK0436717T3 (da) * | 1989-08-02 | 2003-05-05 | Mitra Medical Technology Ab | System til anvendelse ved en fremgangsmåde til terapeutisk eller diagnostisk behandling |
| CA2037933C (en) | 1989-08-02 | 2000-11-07 | Stephen W. Maddock | Method of treatment with medical agents |
| AU8366398A (en) | 1998-07-07 | 2000-01-24 | Department Of Radiation Oncology University Of Washington | Trifunctional reagent for conjugation to a biomolecule |
-
1991
- 1991-01-17 SE SE9100142A patent/SE9100142L/xx not_active Application Discontinuation
-
1992
- 1992-01-15 DE DE69228802T patent/DE69228802T2/de not_active Expired - Lifetime
- 1992-01-15 JP JP50311992A patent/JP3471352B2/ja not_active Expired - Fee Related
- 1992-01-15 WO PCT/SE1992/000020 patent/WO1992012730A1/en not_active Ceased
- 1992-01-15 AT AT92903020T patent/ATE178214T1/de not_active IP Right Cessation
- 1992-01-15 CA CA002100256A patent/CA2100256C/en not_active Expired - Lifetime
- 1992-01-15 US US08/090,047 patent/US6251394B1/en not_active Expired - Fee Related
- 1992-01-15 DK DK92903020T patent/DK0567514T3/da active
- 1992-01-15 ES ES92903020T patent/ES2130167T3/es not_active Expired - Lifetime
- 1992-01-15 EP EP92903020A patent/EP0567514B1/de not_active Expired - Lifetime
-
2000
- 2000-10-12 US US09/689,421 patent/US6723318B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO1992012730A1 (en) | 1992-08-06 |
| DE69228802D1 (de) | 1999-05-06 |
| US6251394B1 (en) | 2001-06-26 |
| EP0567514B1 (de) | 1999-03-31 |
| SE9100142L (sv) | 1992-07-18 |
| DK0567514T3 (da) | 1999-10-18 |
| EP0567514A1 (de) | 1993-11-03 |
| JP3471352B2 (ja) | 2003-12-02 |
| DE69228802T2 (de) | 1999-10-14 |
| ES2130167T3 (es) | 1999-07-01 |
| JPH06504542A (ja) | 1994-05-26 |
| US6723318B1 (en) | 2004-04-20 |
| CA2100256C (en) | 2004-06-08 |
| CA2100256A1 (en) | 1992-07-18 |
| SE9100142D0 (sv) | 1991-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE178214T1 (de) | System zur verbesserten in-vivo aussonderung diagnostischer und/oder therapeutischer wirkstoffe durch extrakorporales entfernen der wirkstoffe | |
| DE3580973D1 (de) | Geraet zur bestrahlung von blutteilen. | |
| ATE121952T1 (de) | Krebsbehandlung. | |
| SE8505438L (sv) | System for uppsamling, behandling och aterforing av en patients blod | |
| ES2188580T3 (es) | Sistema para uso en un metodo de tratamiento terapeutico o de diagnostico. | |
| DE3587266D1 (de) | Verfahren und system zur entfernung von immunosuppressiven bestandteilen aus saeugetierblut. | |
| ATE28571T1 (de) | Schlauchsystem zur behandlung von blut ausserhalb des koerpers and aehnlichen leichtverderblichen fluessigkeiten. | |
| Stone et al. | Mobilization of Radioactive Sodium from the Gastrocnemius Muscle of the Dog. | |
| Ng | New approaches to treatment of chronic pain: a review of multidisciplinary pain clinics and pain centers | |
| SE9202506D0 (sv) | System foer beredning av en medicinsk loesning t ex foer dialys | |
| ITFI20020208A1 (it) | Apparecchiatura utilizzabile in trattamenti di emofiltrazione. | |
| Gourlay et al. | The effect of haemodilution on blood/biomaterial contact-mediated CD11b expression on neutrophils: ex vivo studies | |
| Kyogoku et al. | Clinical and basic studies on the G-1 column, a new extracorporeal therapeutic device effective in controlling rheumatoid arthritis | |
| Duwe et al. | Regulation of DNA synthesis and antibody production by soluble factors released by bone marrow cells | |
| Lewis et al. | Severe haemoptysis associated with viral tracheitis | |
| RU2779225C1 (ru) | Способ лечения больных туберкулезом легких | |
| SU942757A1 (ru) | Способ лечени хронического тонзиллита | |
| SU933084A1 (ru) | Способ лечени острого панкреатита | |
| DE102004010695B4 (de) | Vorrichtung zur Reinigung von Blut | |
| SU1084026A1 (ru) | Способ лечени ишемической болезни сердца | |
| SU1015895A1 (ru) | Способ очистки крови | |
| UA10842C2 (uk) | Спосіб лікуваhhя хроhічhого та хроhічhого рецидивуючого паhкреатитів | |
| Weiskopf | Francisco, San Francisco, California. rbw@ itsa. ucsf. edu | |
| UA15008U (en) | Method of substitution therapy for treating hepatic failure | |
| Franz et al. | Behavior of leucocytes and colony-forming units (CFU-C) in blood of chronic uremic patients during hemodialysis and hemodiafiltration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |